Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 1:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Rapid and long acting insulin Clear all
Completed Phase 3 Interventional Results available

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

NCT02273180
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
SAR342434, Humalog, Insulin glargine HOE901
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
47
States / cities
Tucson, Arizona • Bell Gardens, California • Chula Vista, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 1, 2026, 1:33 PM EDT
Terminated Phase 4 Interventional Results available

Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)

NCT03260868
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
West Des Moines, Iowa • Houston, Texas • Bridgeport, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 1, 2026, 1:33 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients

NCT02496780
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
novolog insulin, levemir insulin, placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
10 Years to 25 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 1, 2026, 1:33 PM EDT
Completed Phase 3 Interventional Results available

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus

NCT02735044
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin glargine,300 U/mL, Insulin glargine (100 units /mL), Background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 17 Years
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
13
States / cities
Tucson, Arizona • Atlanta, Georgia • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 1, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Results available

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

NCT03336528
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Degludec, Glargine, Aspart
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • New York, New York • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 1, 2026, 1:33 PM EDT
Completed Phase 3 Interventional Results available

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine

NCT02294474
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
SAR342434, Humalog, insulin glargine HOE901
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
51
States / cities
Foley, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 1, 2026, 1:33 PM EDT
Completed Phase 3 Interventional

Afrezza® INHALE-1 Study in Pediatrics

NCT04974528
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Afrezza, Rapid-acting Insulin Analog, Basal Insulin
Biological
Lead sponsor
Mannkind Corporation
Industry
Eligibility
4 Years to 17 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
39
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 1, 2026, 1:33 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes

NCT03740919
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
1 Year to 17 Years
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
27
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 1, 2026, 1:33 PM EDT
Terminated Phase 3 Interventional Results available

Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)

NCT00500240
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Insulin Glargine, Insulin Aspart
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 1, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Results available

Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes

NCT02455076
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Exenatide, Glargine, Rapid-acting insulin analogs
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 1, 2026, 1:33 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients

NCT01792830
View directory record Official record
Conditions
Poor Glycemic Control
Interventions
Metformin, Glargine insulin, Glulisine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Oct 1, 2026, 1:33 PM EDT
Completed Phase 3 Interventional Results available

A Study of LY900014 in Participants With Type 1 Diabetes

NCT03214367
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
44
States / cities
Mobile, Alabama • Concord, California • Escondido, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 1, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes

NCT01845831
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Sitagliptin, Basal Bolus, Metformin and Sitagliptin, Glargine, Glargine 50%, Glargine 80%
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Atlanta, Georgia • Ann Arbor, Michigan • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 1, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients

NCT04075513
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin glargine, 300 U/ml, Insulin degludec, 100U/ml, Background therapy: Rapid acting insulin analogs
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 1, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Results available

Glargine U300 Hospital Trial

NCT03013985
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Glargine U300, Glargine U100, Glulisine Insulin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Atlanta, Georgia • Minneapolis, Minnesota • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 1, 2026, 1:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Arterial Stiffness in Type I Diabetes Mellitus

NCT02218268
View directory record Official record
Conditions
Arterial Stiffness in Youth With Type 1 Diabetes
Interventions
Pre-meal bolus, No meal bolus
Drug
Lead sponsor
University of Florida
Other
Eligibility
8 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Oct 1, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Results available

Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.

NCT00591227
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
insulin aspart, insulin detemir
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 1, 2026, 1:33 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Polycystic Ovary Syndrome (PCOS) and Sleep Apnea

NCT00203996
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Obstructive Sleep Apnea
Interventions
continuous positive airway pressure (CPAP), depot leuprolide plus estrogen/progestin replacement, pioglitazone, REM frag, SWS supp
Device · Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 1, 2026, 1:33 PM EDT
Completed Not applicable Interventional Results available

IV Insulin Protocol in Diabetes and Renal Transplantation

NCT00609986
View directory record Official record
Conditions
Kidney Transplantation, Diabetes, Hyperglycemia
Interventions
insulin, NPH Insulin or glargine insulin and aspartame insulin
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2013 · Synced Oct 1, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Results available

Linagliptin Inpatient Trial

NCT02004366
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Linagliptin, Basal Bolus, Linagliptin + 50% Glargine dose on discharge, Linagliptin + 80% Glargine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 1, 2026, 1:33 PM EDT
Terminated Phase 4 Interventional Results available

Oral Anti Diabetic Agents in the Hospital

NCT04416269
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM)
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 1, 2026, 1:33 PM EDT
Not listed No phase listed Observational

Bigfoot Unity Real World Study

NCT05088265
View directory record Official record
Conditions
Type 1 or Type 2 Diabetes
Interventions
Bigfoot Unity Diabetes Management System
Device
Lead sponsor
Bigfoot Biomedical Inc.
Industry
Eligibility
12 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Milpitas, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 1, 2026, 1:33 PM EDT
Completed Early Phase 1 Interventional

Prospective Study of Personalized Approach to Inpatient Patients With Hyperglycemia

NCT03904199
View directory record Official record
Conditions
Hyperglycemia
Interventions
Insulin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 1, 2026, 1:33 PM EDT
Recruiting Phase 4 Interventional

DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes

NCT06445946
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Pregnancy, High Risk
Interventions
Metformin, Insulin
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
1,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
24
States / cities
Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 1, 2026, 1:33 PM EDT